Abstract
A novel series of apigenin derivatives with phloroglucinol or resorcinol as raw materials were synthesized according to Baker-Venaktaraman reaction and their in vitro inhibitory activities on colorectal adenocarcinoma (HT-29) and leucocythemia (HL-60) cell lines were evaluated by the standard methyl thiazole tetrazolium (MTT) method. The results of biological test showed that some of apigenin derivatives possessed stronger anti-cancer activities than apigenin. Compound 6 showed the strongest activity against colorectal adenocarcinoma (HT-29) and leucocythemia (HL-60) cell lines with IC50 valure of 2.03±0.22 µM, 2.25±0.42 µM, it was better than 5-FU (12.92±0.61 µM, 9.56±0.16 µM), which shows a potential compound for colorectal adenocarcinoma and leucocythemia.
Keywords: Anti-cancer activities, apigenin, baker-venkataraman reaction, flavonoids, MTT method, SAR.
Medicinal Chemistry
Title:Synthesis and Anti-cancer Activities of Apigenin Derivatives
Volume: 10 Issue: 7
Author(s): Xing Zheng, Liuying Yu, Jing Yang, Xu Yao, Wenna Yan, Shaowei Bo, Ya Liu, Yun Wei, Zhiyi Wu and Guan Wang
Affiliation:
Keywords: Anti-cancer activities, apigenin, baker-venkataraman reaction, flavonoids, MTT method, SAR.
Abstract: A novel series of apigenin derivatives with phloroglucinol or resorcinol as raw materials were synthesized according to Baker-Venaktaraman reaction and their in vitro inhibitory activities on colorectal adenocarcinoma (HT-29) and leucocythemia (HL-60) cell lines were evaluated by the standard methyl thiazole tetrazolium (MTT) method. The results of biological test showed that some of apigenin derivatives possessed stronger anti-cancer activities than apigenin. Compound 6 showed the strongest activity against colorectal adenocarcinoma (HT-29) and leucocythemia (HL-60) cell lines with IC50 valure of 2.03±0.22 µM, 2.25±0.42 µM, it was better than 5-FU (12.92±0.61 µM, 9.56±0.16 µM), which shows a potential compound for colorectal adenocarcinoma and leucocythemia.
Export Options
About this article
Cite this article as:
Zheng Xing, Yu Liuying, Yang Jing, Yao Xu, Yan Wenna, Bo Shaowei, Liu Ya, Wei Yun, Wu Zhiyi and Wang Guan, Synthesis and Anti-cancer Activities of Apigenin Derivatives, Medicinal Chemistry 2014; 10 (7) . https://dx.doi.org/10.2174/1573406410666140307152557
DOI https://dx.doi.org/10.2174/1573406410666140307152557 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets Current Status of Imaging Infections with Radiolabeled Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Natural Compounds as Antagonists of Canonical Wnt/β-Catenin Signaling
Current Chemical Biology Sphingolipid Signaling Pathways as Potential Therapeutic Targets in Gliomas
Mini-Reviews in Medicinal Chemistry Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer
Current Drug Targets Anti-Cancer Compounds from Terrestrial and Marine Resources -In silico and Experimental Studies
Current Computer-Aided Drug Design Potential for Predicting Toxicity and Response of Fluoropyrimidines in Patients
Current Drug Targets Natural Compounds in Anti-Leukaemic Therapy: A Review
Mini-Reviews in Medicinal Chemistry A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs and Cancer: Towards a Personalized Medicine
Current Molecular Medicine Patent Selections
Recent Patents on DNA & Gene Sequences Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in Flavivirus Antiviral Drug Discovery and Vaccine Development
Recent Patents on Anti-Infective Drug Discovery Nuclear Hormone Receptor Signals as New Therapeutic Targets for Urothelial Carcinoma
Current Cancer Drug Targets Current Prospects of Synthetic Curcumin Analogs and Chalcone Derivatives Against Mycobacterium Tuberculosis
Medicinal Chemistry Comparison of the Structure and Biological Activities of Wild-type and Mutant Liver-targeting Peptide Modified Recombinant Human Endostatin (rES-CSP) in Human Hepatocellular Carcinoma HepG2 Cells
Protein & Peptide Letters Current Status and Future Prospects of C1 Domain Ligands as Drug Candidates
Current Topics in Medicinal Chemistry Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing
Current Drug Delivery Potential of Plant-Derived Natural Products in the Treatment of Leukemia and Lymphoma
Current Drug Targets